- ThirtyFiveBio founded to develop GPR35 antagonists for GI diseases, Oxford UK
About ThirtyFiveBio
Revolutionising gastrointestinal health
ThirtyFiveBio team
Experienced team of drug developers, target experts, investors and clinical KOLs.
James Westcott
CEO
Helen Carlile
Director of Operations
Josselin Caradec
Head of Biology
Chris Luckhurst, PhD
Head of Chemistry
Victoria Perroud
Project Manager
Sochi Otti
EA / Biotech Associate
Board Members
Donmienne Leung
Director, Abbvie Ventures
Tom McCarthy
Executive Chair & co-founder, ThirtyFiveBio
Brent Ahrens
General Partner, Cannan Partners
Nils Lonberg
Exec in Residence, Canaan Partners
James Westcott
CEO
Founders
Tom McCarthy
Co-founder & Executive Chair
Kirsty McCarthy
Co-founder & CEO of MTM
Stuart Hughes
Co-founder & CEO of Nuage Therapeutics
Peter Joyce
Co-founder & CEO of Greywolf Therapeutics
History of ThirtyFiveBio
Founded in 2021 by a team of drug discovery experts and entrepreneurs, ThirtyFiveBio emerged from academic and proprietary analyses showing that GPR35 gain-of-function drives epithelial dysfunction in GI diseases.
Our goal is to break the response ceiling for patients with ulcerative colitis by developing a drug that targets underlying epithelial causality and dysfunction. We aim to have tested this principle in patients by 2028.
“Human colitis is an epithelial disease and novel modalities are required to tackle this”.
- ThirtyFiveBio founded to develop GPR35 antagonists for GI diseases, Oxford UK
2021
- Data emerges showing strong GPR35 genetic association with IBD is driven by gain-of-function variance
- GPR35 KO is protective in bacterial model of murine colitis
- Scientific advisory team
2022-23
- GPR35 antagonist discovery and optimisation and bioscience
2024
- Advanced lead molecule with 3 series under patent protection
- Synthetic route, scale up of lead antagonist
- Translational research collaboration with the Kennedy Institute
- Raising syndicated Series A to progress to clinic
2025
- Preclinical development candidate
- Preclinical PoC in patient-derived colitis epithelium
- KOL translational advisory group
2026+
- Clinic enabling
- First-in-human 1H 2027
2021
- $20M seed round Canaan Partners
- Data emerges showing strong GPR35 genetic association with IBD is driven by gain-of-function variance
- Scientific advisory team
2022-23
- Innovate UK BMC £0.7M grant (Translational Grant)
- GPR35 antagonist discovery and optimisation and bioscience
2024
- Second Innovate UK BMC £0.7M grant (Precision Medicine Grant)
- Advanced lead molecule with 3 series under patent protection
- Synthetic route, scale up of lead antagonist
- Translational research collaboration with the Kennedy Institute
2025
- AbbVie Ventures invest alongside Canaan Partners and Mayewell Capital
- Raising syndicated Series A to progress to clinic
- Preclinical development candidate
- Preclinical PoC in patient-derived colitis epithelium
- KOL translational advisory group
2026
- Clinic enabling
- First-in-human 1H 2027
Proud to be part of the Molecule to Medicine Ecosystem
Molecule to Medicine (MTM), has expertise in founding biotech companies and supplying integrated, stage-appropriate business operations and R&D services to enable successful progression from set-up to clinic.
Companies supported by MTM operate as part of an Ecosystem: a unique arrangement which generates value by leveraging the expertise of its native network of drug discovery professionals and its robust operational model.
Ecosystem companies, including ThirtyFiveBio, accelerate their development of novel therapeutics, sharing learning from previous experience through this collaborative internal and external networks and partners.
Our values
Innovation
We use creative thinking to explore new ideas and ways of working, executing on our purpose and learning from our experiences.
Teamwork
We operate with respect, openness and transparency to deliver on our shared mission.
Excellence
We are striving to be the best in everything we do. We are accountable for our actions, resilient and courageous in our approach.
Momentum
We operate using agile methodologies to proactively drive the efficient delivery of our mission.
